Matteo Duca

1.0k total citations
18 papers, 143 citations indexed

About

Matteo Duca is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matteo Duca has authored 18 papers receiving a total of 143 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matteo Duca's work include Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (3 papers). Matteo Duca is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (3 papers). Matteo Duca collaborates with scholars based in Italy, United States and Belgium. Matteo Duca's co-authors include Silvia Damian, Sara Cresta, Filippo de Braud, Massimo Barberis, Biagio Paolini, Tommaso Martino De Pas, Chiara Lazzari, Sylvie Rottey, Luigi Mariani and Cristina Noberasco and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Matteo Duca

17 papers receiving 141 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matteo Duca Italy 5 81 57 40 36 17 18 143
Blanca Navarro Rodrigo Switzerland 3 115 1.4× 38 0.7× 33 0.8× 79 2.2× 10 0.6× 6 160
Hanmei Lou China 6 96 1.2× 28 0.5× 19 0.5× 42 1.2× 17 1.0× 14 154
Iris Wang United States 6 100 1.2× 31 0.5× 23 0.6× 59 1.6× 5 0.3× 13 148
Rebecca Ibrahim France 5 106 1.3× 32 0.6× 25 0.6× 19 0.5× 39 2.3× 10 141
Georgia Spain United Kingdom 4 97 1.2× 25 0.4× 90 2.3× 69 1.9× 17 1.0× 6 164
Keisuke Onoi Japan 3 114 1.4× 72 1.3× 23 0.6× 42 1.2× 16 0.9× 5 157
Xu-Shan Sun France 7 124 1.5× 80 1.4× 36 0.9× 31 0.9× 5 0.3× 13 193
Mohammad Atiq United States 6 88 1.1× 64 1.1× 54 1.4× 49 1.4× 12 0.7× 21 155
Julia Dudnik Israel 9 86 1.1× 89 1.6× 32 0.8× 17 0.5× 8 0.5× 23 143
Dingwei Ye China 7 139 1.7× 61 1.1× 77 1.9× 11 0.3× 52 3.1× 12 200

Countries citing papers authored by Matteo Duca

Since Specialization
Citations

This map shows the geographic impact of Matteo Duca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matteo Duca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matteo Duca more than expected).

Fields of papers citing papers by Matteo Duca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matteo Duca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matteo Duca. The network helps show where Matteo Duca may publish in the future.

Co-authorship network of co-authors of Matteo Duca

This figure shows the co-authorship network connecting the top 25 collaborators of Matteo Duca. A scholar is included among the top collaborators of Matteo Duca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matteo Duca. Matteo Duca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lorenzini, Daniele, Chiara Costanza Volpi, Monica Niger, et al.. (2025). Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization. Tumori Journal. 111(4). 322–330. 1 indexed citations
2.
Rivoltini, Licia, Chiara Camisaschi, Giovanni Fucà, et al.. (2024). Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade. Scientific Reports. 14(1). 3379–3379. 6 indexed citations
3.
Cresta, Sara, Anna Tessari, Antonella Aiello, et al.. (2024). 114P Effects of chemotherapy on TREG lymphocytes in early breast cancer. ESMO Open. 9. 102339–102339. 1 indexed citations
4.
Rottey, Sylvie, Jeffrey Clarke, Kyaw Aung, et al.. (2022). Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. EUR Research Repository (Erasmus University Rotterdam). 40 indexed citations
5.
Capone, Iolanda, Fabio Bozzi, Gian Paolo Dagrada, et al.. (2022). Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples. SHILAP Revista de lepidopterología. 3(5). 582–597. 3 indexed citations
6.
Ambrosini, Margherita, Giovanni Fucà, Matteo Duca, et al.. (2021). Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?. Critical Reviews in Oncology/Hematology. 169. 103532–103532. 4 indexed citations
7.
Ribrag, Vincent, Jean‐Marie Michot, Brigette Ma, et al.. (2021). Phase I/II Study of MAK683 in Patients with Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma. Blood. 138(Supplement 1). 1422–1422. 5 indexed citations
8.
Braud, Filippo de, Jean‐Pascal Machiels, Daniela Boggiani, et al.. (2020). A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. Cancers. 12(6). 1425–1425. 4 indexed citations
9.
Mariani, Gabriella, Giulia Galli, Stefano Cavalieri, et al.. (2019). Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. The Breast Journal. 25(2). 237–242. 3 indexed citations
10.
Tessari, Anna, Lorenzo Pilla, Silvia Damian, et al.. (2018). Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?. The Breast. 42. 68–73. 27 indexed citations
11.
Farè, Elena, Silvana Sdao, Silvia Damian, et al.. (2018). Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?. Annals of Oncology. 29. viii430–viii430. 2 indexed citations
12.
Gelsomino, Francesco, Maria Rita Castellani, Alfonso Marchianò, et al.. (2016). Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. Journal of Thoracic Disease. 8(6). E403–E407. 3 indexed citations
13.
Braud, Filippo de, Jean‐Pascal Machiels, Marcello Tiseo, et al.. (2016). Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2545–2545. 1 indexed citations
14.
15.
Agustoni, Francesco, et al.. (2014). Folfirinox in Pancreatic Cancer: the National Cancer Institute of Milan Single Experience. Annals of Oncology. 25. ii50–ii50. 1 indexed citations
16.
Moliterni, Angela, Gabriella Mariani, G Stella, et al.. (2014). Long-term results from INT-HER study: Retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patients—Single institution experience.. Journal of Clinical Oncology. 32(15_suppl). e11509–e11509. 1 indexed citations
17.
Conforti, Fabio, Chiara Catania, Francesca Toffalorio, et al.. (2013). EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung. Lung Cancer. 81(3). 440–444. 34 indexed citations
18.
Bianchi, Giulia, et al.. (2013). Metastatic Breast Cancer Treated with Lapatinib with a Prolonged Benefit: A Case Report and a Review of Therapeutic Options Available. Tumori Journal. 99(6). e269–e272. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Blanca Navarro Rodrigo Breakdown of academic impact, for papers by Hanmei Lou Breakdown of academic impact, for papers by Iris Wang Breakdown of academic impact, for papers by Rebecca Ibrahim Breakdown of academic impact, for papers by Georgia Spain Breakdown of academic impact, for papers by Keisuke Onoi Breakdown of academic impact, for papers by Xu-Shan Sun Breakdown of academic impact, for papers by Mohammad Atiq Breakdown of academic impact, for papers by Julia Dudnik Breakdown of academic impact, for papers by Dingwei Ye
Rankless by CCL
2026